Eleison Pharmaceuticals

Eleison Pharmaceuticals is a private, pre-revenue biotech advancing a portfolio of three small molecule oncology candidates, all with Orphan Drug Designation. Its lead asset, glufosfamide, is in a pivotal Phase III trial for second-line pancreatic cancer, with top-line data expected in 2027. The company's strategy centers on developing 'uncommon therapies' for rare cancers by leveraging metabolic targeting to improve drug delivery and reduce toxicity.

Development of cancer therapies that exploit altered tumor cell metabolism for targeted drug delivery, exemplified by glucose-conjugated chemotherapeutics and lipid-complexed formulations for inhaled delivery.

In pancreatic cancer, glufosfamide would compete with existing second-line options like 5-FU-based regimens and nanoliposomal irinotecan, as well as numerous investigational targeted and immunotherapies. For ILC, the competitive landscape includes other inhaled oncology therapies in development and standard intravenous chemotherapies for lung cancer and osteosarcoma.